Pegvaliase · PALYNZIQ
Protein / enzyme therapeutic
Evidence outlook
Approved: Phenylketonuria
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Treatment of phenylketonuria
- Phenylketonuria in patients aged 16 years and older
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
Prism301 NCT01819727 · Phenylketonuria This open-label study randomized participants between two doses of pegvaliase, with no placebo or other-treatment comparison group. Its primary endpoint counted hypersensitivity reactions only, so it makes no controlled test of whether pegvaliase works. Registry: NCT01819727 | 3 | Number of Participants With Hypersensitivity Adverse Reaction (baseline and 36 weeks) 2015-11-25 | Number of Participants With Hypersensitivity Adverse Reaction (baseline and 36 weeks): BMN 165, 20mg/Day 111 Participants | BMN 165, 40mg/Day 119 Participants | Weak signal | link ↗ |
View 2 more trials
NCT03694353 NCT03694353 · Phenylketonuria This was an open-label continuation of participants from parent studies 165-302 or PAL-003, with 37 participants receiving pegvaliase and no randomized control group or blinding. Blood phenylalanine and safety were reported descriptively, so there was no controlled primary-endpoint comparison to determine whether the endpoint was met. Registry: NCT03694353 | 3 | Number of Participants With Treatment-emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0 (Up to Day 741 (approximately Week 106)); Change in Blood Phe Concentration (The Outcome Measure Data Table below uses the 'analysis visit' as defined by the mapping rule in the SAP. The last Phe measurement was mapped to 'analysis visit' week 121. The actual date of the last Phe measurement was day 836 (approximately Week 119).) 2021-01-13 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
PEGASUS NCT05270837 · Phenylketonuria Participants were randomised to pegvaliase or a diet-only control and the primary efficacy comparison, change in blood phenylalanine (the disease-defining measure in PKU), was clearly met. The trial was open-label and small (55 participants), so knowledge of treatment could influence diet and reporting, which limits how strongly the result can be trusted. Registry: NCT05270837 | 3 | Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study. (Baseline to Week 72 (average of the Week 69 and Week 73)); Incidence of Treatment-emergent Adverse Events (Part 1) (Up to Week 73); Percentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb) (Baseline (Day 1), Week 73); Percentage of Participants With Positive PAL IgG Antibody (Baseline (Day 1), Week 73); Percentage of Participants With Positive PAL IgM Antibody (Baseline (Day 1), Week 73); Percentage of Participants With Positive PEG IgG Antibody (Baseline (Day 1), Week 73); Percentage of Participants With Positive PEG IgM Antibody (Baseline (Day 1), Week 73); Percentage of Participants With Positive Neutralizing Antibodies (NAb) (Baseline (Day 1), Week 73) 2025-01-14 | Primary results reported. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 4 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Phenylketonuria: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Pegvaliase (PALYNZIQ): this drug | Approved | Protein / enzyme therapeutic | Phenylalanine ammonia lyase (enzyme substitution) | Weak signal | Featured results are safety only in this race | |
| Sapropterin Dihydrochloride (Kuvan) | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36) NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009). | |
| Sepiapterin | Approved | Small molecule | Phenylalanine hydroxylase (PAH) | Reliable signal | No reviewed efficacy summary in this indication | |
| BEAM-304 | —(overall) | Gene therapy / editing | PAH gene (phenylalanine hydroxylase) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow PALYNZIQ (Pegvaliase) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent